A double-blind controlled study of viloxazine against placebo in elderly depressed patients with a primary diagnosis of depressive illness records statistically significant improvements in depression ratings in the viloxazine group after three weeks.
Viloxazine was effective and well tolerated at doses of 100 to 200 mg in depressed elderly patients, several of whom had concurrent cardiac disease.
Get full access to this article
View all access options for this article.
References
1.
AmaducciL (1975) Multicentre studies with viloxazine (Vivalan). Journal of International Medical Research3, Suppl 3, 95.
2.
BaylissP F CDuncanS M (1974) The clinical pharmacology of viloxazine hydrochloride – a new antidepressant of novel chemical structure. British Journal of Clinical Pharmacology1, 431.
3.
BrosnanR DBusbyA MHollandR P C (1976) Cases of overdosage with viloxazine hydrochloride (Vivalan). Journal of International Medical Research4, 83.
4.
CronholmBOttossonJ O (1960) Experimental studies of the therapeutic action of electroconvulsive therapy in endogenous depression. Acta Psychiatrica Scandinavica35, Suppl 145, 69.
5.
CronholmBOttossonJ O (1963) Ultrabrief stimulus technique in electro-convulsive therapy. Journal of Nervous and Mental Diseases137, 268.
6.
De WildeJ (1977) Double-blind controlled trial of viloxazine hydrochloride and imipramine hydrochloride in the treatment of hospital depressed patients. Acta Therapeutica3, 49.
7.
EdwardsJ G (1977) Viloxazine: Assessment of potential rapid antidepressant action. British Medical Journal2, 1327.
8.
FloruLCzarnyGTegelerJ (1976) Double-blind study with the novel antidepressant viloxazine versus imipramine in 50 patients. Arzneimittel Forschung26, 1170.
9.
RojoR Gomez (1976) Controlled double-blind study of viloxazine and impramine in depression. Hospital General16, 26.
10.
GottfriesC GGottfriesI (1969) Geriatriskt Skattningsschema. Stencil St Lars Hospital, Lund.
11.
JacobssonLvon KnorringL (1976) Clinical experiences with a new antidepressive, ICI 58,834. Psychiatrie Neurologie Medizinische Psychologic Leipzig28, 114.
12.
MagnusR V (1975) A placebo-controlled trial of viloxazine with and without tranquillizers in depressive illness. Journal of International Medical Research3, 207.
13.
MahapatraS B (1975) Short-term effects of viloxazine (Vivalan) compared with placebo in depression: A double-blind study. Journal of International Medical Research3, Suppl 3, 70.
14.
MallionK BToddA HTurnerR WBainbridgeJ GGreenwoodD TMadinaveitiaJSomervilleA RWhittleB A (1972) 2-(2-Ethoxyphenoxymethyl) tetra-hydro-1, 4-oxazine hydrochloride, a potential psychotropic agent. Nature239, 157.
15.
PinderR MBrogdenR NSpeightT MAveryG S (1977) Viloxazine: A review of its pharmocological properties and therapeutic efficacy in depressive illness. Drugs13, 401.
16.
RenfordtEBuschHFaehndrichEOerlinghausenB Mueller (1976) Investigations of a new antidepressive substance (viloxazine). Arzneimittel Forschung26, 1114.
17.
RoutsonisKMichaelidesGPassalidesTh (1976) The use of viloxazine (Vivalan) in depressive states. (Double-blind trial involving in-patients). Acta Psychiatrica Neurologica Hellenica12, 109.
